Patients with Crohn's disease and ulcerative colitis face a high disease burden.
Chetan Karyekar, MD, PhD
Advertisement
VP, late development, immunology at The Janssen Pharmaceutical Companies of Johnson & Johnson.
Articles by Chetan Karyekar, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Novo Nordisk Sends Amended Acquisition Proposal to Metsera
2
Pharmaceutical Executive Daily: Kimberly-Clark’s $48.7 Billion Acquisition of Kenvue
3
FDA Approves Kygevvi Becoming the First Treatment for Thymidine Kinase 2 Deficiency
4
Roundup: Pharma Industry Forms Strategic Collaborations Bolstering Research and Development Pipelines for Autoimmune and Oncology Therapies
5
